Contrast Agents: Magnetic Resonance
- 1 January 2008
- book chapter
- Published by Springer Nature
- p. 135-165
Abstract
Even though the intrinsic magnetic resonance imaging (MRI) contrast is much more flexible than in other clinical imaging techniques, the diagnosis of several pathologies requires the involvement of contrast agents (CAs) that can enhance the difference between normal and diseased tissues by modifying their intrinsic parameters. MR CAs are indirect agents because they do not become visible by themselves as opposed to other imaging modalities. The signal enhancement produced by MRI CAs (i.e., the efficiency of the CAs) depends on their longitudinal (r1) and transverse (r2) relaxivity (expressed in s−1 mmol−1 1), which is defined as the increase of the nuclear relaxation rate (the reciprocal of the relaxation time) of water protons produced by 1 mmol per liter of CA. Paramagnetic CAs (most of them complexes of gadolinium) are frequently used in clinics as extracellular, hepatobiliary or blood pool agents. Low molecular weight paramagnetic CAs have similar effects on R1 and R2, but the predominant effect at low doses is that of T1 shortening (and R1 enhancement). Thus, organs taking up such agents will become bright in a T1-weighted MRI sequence; these CAs are thus called positive contrast media. The CAs known as negative agents influence signal intensity mainly by shortening T2* and T2, which produces the darkening of the contrast-enhanced tissue. These CAs are generally composed of superparamagnetic nanoparticles, consisting of iron oxides (magnetite, Fe3O4, maghemite, γFe2O3, or other ferrites). Iron oxide nanoparticles are taken up by the monocyte-macrophage system, which explains their potential application as MRI markers of inflammatory and degenerative disorders. Most of the contemporary MRI CAs approved for clinical applications are non-specific for a particular pathology and report exclusively on the anatomy and the physiological status of various organs. A new generation of MRI CAs is progressively emerging in the current context of molecular imaging, agents that are designed to detect with a high specificity the cellular and molecular hallmarks of various pathologies.Keywords
This publication has 118 references indexed in Scilit:
- Recent advances in iron oxide nanocrystal technology for medical imaging☆Advanced Drug Delivery Reviews, 2006
- Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamideEuropean Radiology, 2006
- Central nervous system inflammatory response after cerebral infarction as detected by magnetic resonance imagingNMR in Biomedicine, 2004
- Optimising the design of paramagnetic MRI contrast agents: influence of backbone substitution on the water exchange rate of Gd-DTPA derivativesMagnetic Resonance Materials in Physics, Biology and Medicine, 2004
- Molecular imaging in drug discovery and developmentNature Reviews Drug Discovery, 2003
- Magnetic relaxation switches capable of sensing molecular interactionsNature Biotechnology, 2002
- Magnetic Resonance Imaging Detects a Specific Peptide−Protein Binding EventJournal of the American Chemical Society, 2002
- Prototropic and Water-Exchange Processes in Aqueous Solutions of Gd(III) ChelatesAccounts of Chemical Research, 1999
- Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and RatsInvestigative Radiology, 1995
- Preclinical Safety Assessment and Pharmacokinetics of Gadodiamide Injection, a New Magnetic Resonance Imaging Contrast AgentInvestigative Radiology, 1993